Clinical utility of reverse phase protein array for molecular classification of breast cancer
暂无分享,去创建一个
Patrick J Tighe | Ian O Ellis | I. Ellis | A. Green | E. Rakha | P. Tighe | C. Nolan | O. Negm | M. Hamed | M. Aleskandarany | M. Diez-Rodriguez | Andrew R Green | A. Muftah | D. Ahmad | Emad A Rakha | Christopher C Nolan | Ola H Negm | Abir A Muftah | Mohammed A Aleskandarany | Mohamed R Hamed | Dena A J Ahmad | Maria Diez-Rodriguez | A. Green | Abir A. Muftah
[1] Gallya Gannot,et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. , 2002, The American journal of pathology.
[2] H. Höfler,et al. Guided protein extraction from formalin‐fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains , 2008, Proteomics. Clinical applications.
[3] R. Elledge,et al. Prognostic and predictive value of p53 and p21 in breast cancer , 2004, Breast Cancer Research and Treatment.
[4] Heiko A. Mannsperger,et al. RPPanalyzer: Analysis of reverse-phase protein array data , 2010, Bioinform..
[5] P. Tighe,et al. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS) , 2014, European journal of immunology.
[6] G. Ball,et al. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer , 2014, British Journal of Cancer.
[7] A. Tanca,et al. Generation of high‐quality protein extracts from formalin‐fixed, paraffin‐embedded tissues , 2009, Proteomics.
[8] C. Schmidt,et al. Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification , 2010, Proteome Science.
[9] Michael Pawlak,et al. Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays , 2013, Molecular & Cellular Proteomics.
[10] K. Syrigos,et al. Analytic Variability in Immunohistochemistry Biomarker Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[11] C. Schmidt,et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs , 2012, Oncogenesis.
[12] Mariaelena Pierobon,et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.
[13] Stefan Wiemann,et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer , 2012, Molecular systems biology.
[14] Stefan Wiemann,et al. Infrared‐based protein detection arrays for quantitative proteomics , 2007, Proteomics.
[15] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.
[16] E. Petricoin,et al. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.
[17] R. Casadonte,et al. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry , 2011, Nature Protocols.
[18] K. Coombes,et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.
[19] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[20] T. Veenstra,et al. Unravelling the proteome of formalin-fixed paraffin-embedded tissue. , 2006, Briefings in functional genomics & proteomics.
[21] E. Petricoin,et al. One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens , 2011, PloS one.
[22] J. Nährig,et al. Quantitative protein analysis from formalin‐fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis , 2007, The Journal of pathology.
[23] E. Petricoin,et al. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. , 2011, The American journal of pathology.
[24] J. Langridge,et al. Initial Development and Validation of a Novel Extraction Method for Quantitative Mining of the Formalin-Fixed, Paraffin-Embedded Tissue Proteome for Biomarker Investigations , 2010, Journal of proteome research.
[25] G. Ball,et al. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.
[26] S. Nishizuka,et al. Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.
[27] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[28] Yanxiang Cao,et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. , 2009, Archives of pathology & laboratory medicine.
[29] K. Becker,et al. Producing reverse phase protein microarrays from formalin-fixed tissues. , 2011, Methods in molecular biology.
[30] Emanuel F Petricoin,et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. , 2007, Cancer genomics & proteomics.
[31] I. Ellis,et al. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study , 2014, Breast Cancer Research and Treatment.
[32] D. Barnes,et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.